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E-mail address: noah@bgu.ac.il (N. Isakov).Members of the protein kinase C (PKC) family of serine/threonine kinases have been implicated in
several physiological processes regulating the activation response of platelets. They are involved
in processes leading to granule secretion, integrin activation, platelet aggregation and spreading,
and procoagulation. The protein kinase C h (PKCh) isoform, which was originally identiﬁed in T lym-
phocytes, is also expressed at relatively high levels in platelets, wherein it is involved in the regula-
tion of hemostasis and thrombosis. Recent studies suggest a role for PKCh in protease-activated
receptor (PAR)-, glycoprotein VI (GPVI) receptor- and glycoprotein aIIbb3 integrin receptor-linked
signal transduction pathways. The present review focuses on the latest observations relevant to
the role of PKCh in platelet activation.
 2011 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Platelets, also termed thrombocytes, are small, anucleated cells,
which are formed in the bone marrow by pinching off cytoplasmic
fragments of megakaryocytes. Their average lifespan is 5–9 days,
they circulate in the blood, and are critical for hemostasis and clot
formation in response to vascular injury. They are also involved in
restenosis and inﬂammatory reactions [1–3]. Upon activation,
platelets secrete a multitude of soluble effector molecules that
stimulate the deposition of extracellular matrix and promote heal-
ing of damaged tissue [1–3]. A decreased number or reduced activ-
ity of platelets may result in prolonged bleeding times and
increased blood loss following injury, while an increased number
or excessive activity of platelets can lead to intravascular clot
formation, circulating emboli and occlusion of blood vessels [1–3].
Platelet interaction with soluble blood constituents or vascular
wall components is mediated by speciﬁc surface receptors, which
promote adhesion to adjacent platelets, leukocytes, endothelial
cells and extracellularmatrices. This can result in platelet activationalf of the Federation of European Band ampliﬁcation of thrombo-inﬂammatory reactions [4]. Adher-
ence of platelets to injured vasculature induces granule secretion,
synthesis of thromboxane A2 (TxA2), extension of ﬁlopodia and
lamellipodia and activation of surface adhesion molecules [4].
Many of these functions are regulated, at least in part, by members
of the protein kinase C (PKC) family [5]. In this review, we will dis-
cuss some of the recent ﬁndings concerning the isoform-speciﬁc
roles of PKCh in platelets, focusing on results obtained using plate-
lets of PKC-deﬁcient mice.
2. Platelet activation
Platelet activation plays an important role in hemostasis and
thrombus formation. Under normal physiological conditions, plate-
lets circulate in the blood as resting cells, where they continuously
encounter inhibitory signals provided by endothelial cells that line
the inner surface of the blood vessels [6]. Vascular endothelial cells
produce nitric oxide that inhibits platelet activation, and soluble
ADPase, which degrades the platelet activator, ADP. Endothelial
cells also produce the eicosanoid prostacyclin (PGI2) that can asso-
ciate with the Gs protein-coupled prostacyclin receptor on the
surface of platelets. PGI2 binding to its cognate receptor, signalsiochemical Societies. Open access under CC BY-NC-ND license.
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platelet activator, TXA2, thereby inhibiting platelet activation [1,2].
Vascular endothelial cells adhere to the blood vessel basement
membrane by physical binding to the collagen. They also associate
with the von Willebrand factor (vWF) that functions as a cell adhe-
sion ligand and increases the binding afﬁnity of the endothelial
cells to the extracellular matrix [7,8]. Under physiological condi-
tions, the collagen is not exposed to the bloodstream. However, a
trauma to the vascular endothelial layer exposes collagen and
vWF from the subendothelium to the bloodstream, making them
accessible to platelets that respond by a rapid turn-on of several
biochemical cascades [7,8]. For example, binding of the platelet
receptor glycoprotein VI (GPVI) to collagen initiates a signaling
cascade leading to platelet activation, which is characterized by
the release of granule-stored mediators and synthesis of thrombin
and TXA2 [9]. Secreted mediators, such as adenosine diphosphate
(ADP), serotonin, platelet-activating factor (PAF), vWF, and TXA2
activate additional platelets and further amplify the intensity of
the entire response. In addition, stimulation of platelets results in
the expression of proteins that enable them to adhere to speciﬁc
receptors on the surface of leukocytes and endothelial cells [9].
This mechanism is mediated by proteins such as P selectins (P
stands for platelet; also termed CD62P), which are normally stored
in a-granules within the cytoplasm of resting platelets, but move
to the platelet’s outer surface upon their activation. They can then
interact with P-selectin glycoprotein ligand-1 (PSGL1; also termed
Selectin P ligand (SELPLG) or CD162) and other ligands on the sur-
face of the leukocytes or endothelial cells [10].
Molecules that belong to a different type of a receptor family,
termed PARs (protease activated receptors) are G-protein coupled
receptors that undergo activation by the action of serine proteases
that cleave an extracellular portion of the receptor. The cleaved N-
terminal peptide acts as a tethered ligand or agonist, which acti-
vates the PAR receptor and initializes a physiological response.
Both GPVI and PARs receptors can stimulate phospholipase C
(PLC), leading to the generation of second messengers, which acti-
vate PKC and stimulate the release of calcium ions from intracellu-
lar stores, respectively [11]. Activation of this signaling pathway is
an early step in biochemical processes regulating many of the func-
tional responses of platelets.
Platelet activation also results in scramblase-mediated trans-
port of negatively charged phospholipids to the platelet surface.
These phospholipids provide a catalytic surface (with the charge
provided by phosphatidylserine and phosphatidylethanolamine)
for the tenase complex (formed by the activated forms of the blood
coagulation factor VIII and factor I).
Platelet aggregation involves an additional type of receptor that
speciﬁcally associates with ﬁbrinogen, the glycoprotein aIIbb3 inte-
grin receptor. Fibrinogen binding to platelet aIIbb3 triggers ‘outside-
in’ signals that promote actin polymerization and cell spreading
[12]. In contrast, aIIbb3 inhibitors prevent platelet aggregation and
thrombus formation and are therefore useful for treating patients
with acute coronary syndromes.
Platelets contain two types of morphological distinct storage
granules, the a-granules and the dense granules. Release of soluble
mediators from the a-granules amplify the coagulation cascade at
the site of the vascular injury and increase the platelets’ procoagula-
tion activity. Release of soluble mediators from the dense granules,
predominantly the ADP, promotes the recruitment of additional
platelets to the site of injury.3. Protein kinase C (PKC)
PKC is a ubiquitous family of structurally related serine/threo-
nine kinases that are part of the AGC-type kinase (PKC/PKG/PKC)superfamily [13]. The PKC family consists of at least 10 distinct iso-
forms that are grouped into three classes: the classical (cPKC), no-
vel (nPKC) and atypical (aPKC) enzymes. Members of the cPKC (a,
bI, bII, and c) utilize both Ca2+ ions and diacylglycerol (DAG) as
cofactors for activation, the nPKC (d, e, g, and h) utilize DAG, but
are Ca2+-independent, and the aPKC (f and i/k) that are active inde-
pendent of Ca2+ or DAG. Different PKC isoforms exhibit some over-
lapping functions as well as distinct, non-redundant functions,
which depending on the experimental system used, can exhibit
speciﬁc biochemical properties, expression proﬁles, and physiolog-
ical functions. They can differ also in subcellular localization, and
although the majority of PKC enzymes reside in the cytoplasm of
resting cells, they translocate to the plasma membrane [14,15], nu-
clear membrane [16], or other subcellular compartments [17–19],
following stimulation of cells with a large variety of physiological
agonists. The redistribution of distinct PKC isoforms to speciﬁc
subcellular compartments is critical for the induction of PKC cata-
lytic activity, since the speciﬁc location determines the enzyme’s
ability to interact with selected cofactors and has access to speciﬁc
substrates. The differential subcellular distribution of PKC is, at
least partially, regulated by PKC-binding proteins, such as RACKs
(receptor for activated C kinase) [20], scaffold proteins, including
AKAP (a kinase-anchoring protein) [21], and cytoskeletal elements,
including actin [18,22]. PKC enzymes play a major role in the sig-
naling networks that translate environmental signals into cellular
behavior. By phosphorylating speciﬁc substrates and altering their
conformation and/or biological activity PKC can regulate multiple
cellular functions.4. PKCh
The human PKCh gene (termed PRKCQ) was ﬁrst discovered in
1993, in a search for new PKC isoforms that are potentially involved
in the regulation of T cell responses [23]. Relatively high expression
levels of PKCh were found in T lymphocytes and lymphoid organs,
skeletal muscle, lung and kidney [23–26]. Among the hematopoi-
etic cell lineages tested, high levels of PKCh were observed in T
but not B lymphocytes and in representatives of the megakaryoid
cell lineage, including megakaryocytes and platelets [24,27,28].
PKCh is unique among the PKC isoforms in its ability to translo-
cate from the cytosol to the center of the immunological synapse
of activated T cellswhere it colocalizeswith the TCR [29,30]. It is also
involved in cytoskeletal remodeling and contributes to the forma-
tionof the rearranged synapse [31]. Translocation of PKChwas found
to be regulated by the Lck protein tyrosine kinase and correlated
with the catalytic activation of PKCh by inducible cofactors that
are produced along the PI3K- and Vav-dependent pathway [32].
Inherited deﬁciency of PKCh in mice has no effect on thymocyte
development but it impairs TCR-induced activation response in
mature T cells [33]. As a result, proliferative responses of anti-
gen-triggered PKCh-deﬁcient mature T cells are inhibited, predom-
inantly because of reduced production of IL-2 and decreased
expression of CD25, the high afﬁnity subunit of the IL-2 receptor
[33]. It is suggested therefore that PKCh plays a critical role in
transduction of essential signals downstream of activated T cell
antigen receptors [34]. This suggestion is in agreement with the
fact that TCR-stimulated PKCh-deﬁcient mature T cells fail to re-
spond by upregulation of the AP-1, NF-AT and NF-kB transcription
factors [33,35]. These effects may possibly account for the defect in
IL-2 production, since the IL-2 gene promoter possesses critical
binding sites for AP-1, NF-kB and NF-AT transcription factors, in
addition to the Oct-1 [36].
More recent studies with PKCh-deﬁcient mice demonstrated
the need for PKCh during the differentiation of T cells into speciﬁc
cell lineages. For example, PKCh was found to be essential for the
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helminth Nippostrongylus brasiliensis, or the parasite Leishmania
major, and during allergic lung inﬂammation induced by an in-
haled allergen [37–39]. Th1-mediated responses in these three
models were almost unaffected [37,38]. Furthermore, studies in
primary PKCh/ CD8+ T cells activated by peptide-MHC com-
plexes revealed severe defects in ERK and JNK (but not p38) acti-
vation [40], suggesting the involvement of PKCh in the induction of
optimal Tc-mediated immune responses.
Whereas the in vitro and in vivo responses of PKCh-deﬁcient T
cells have been thoroughly investigated, understanding the role
of PKCh in platelets functions is only at its early phase.5. PKC in platelet activation
Initial studies suggesting a role of PKC in platelet activation
were based on the utilization of broad-spectrum PKC inhibitors
that suppressed or abolished a wide range of platelet functions,
including granule secretion and aggregation [41–43]. Likewise,
PKC activators were found to enhance platelet responses [44–46].
These studies were supported by PKC isoform expression anal-
yses showing that both human and mouse platelets express rela-
tively high levels of the PKCa, bI, bII, d, and h isoforms, and low
or undetectable levels of PKCg, e, and f [28,47–51].
The development of inhibitors with preferential activity towards
speciﬁc PKC isoforms has led to the understanding that different
receptor-linked signaling pathways can utilize distinct PKC iso-
forms, which in turn, can phosphorylate and regulate the activity
of different effector molecules. However, in vivo studies with such
inhibitors were not satisfactory due to the partial cross-reactivity of
these drugs, and their partial inhibition of other PKC isoforms.
Genetic models in which the expression of a single PKC gene is
modiﬁed represented an alternative approach. However, platelets
are anucleated cells and therefore not amenable to genetic manip-
ulation by gene overexpression or silencing. As a result, the utiliza-
tion of platelets from genetically modiﬁed mice that lack one or
more PKC isoform is the preferred approach for the study of PKC
isoform-speciﬁc functions.
Accumulated information based on the utilization of platelets
from PKC ‘KO mice’, in addition to the PKC isoform selective inhib-
itors, suggests that PKC enzymes contribute to the regulation of an
array of platelet functions, including Ca2+ entry [52,53], ‘outside-in’
signaling [54,55], exocytosis and secretion of storage granules
[47,49,56], aIIbb3 integrin activation [55], actin-mediated ﬁlopodia
formation [57] and platelet adherence to extracellular matrix or
cells [58]. This information and additional data indicated that
PKC plays a role in multiple biochemical processes leading to plate-
let aggregation, coagulation and thrombus formation.
Platelet agonists interact with several different surface recep-
tors, which are linked to unique signaling pathways, and some of
these pathways converge on the activation of PKC. Furthermore,
many receptors that regulate platelet activation are G-protein-cou-
pled receptors. Upon agonist stimulation, they activate PLC, which
catalyzes the hydrolysis of the membrane phospholipid phosphati-
dylinositol 4,5-bisphosphate (PIP2) into two types of second mes-
sengers, inositol 1,4,5-trisphosphtae (IP3) and 1,2-diacylglycerol
(DAG). The hydrophobic DAG remains within the membrane envi-
ronment where it serves as a cofactor for activation of different
cPKC and nPKC isoforms. The hydrophilic IP3 binds to and opens li-
gand gated ion channels, which allows the release of Ca2+ ions into
the cytosol where they activate multiple Ca2+-dependent enzymes,
including cPKC [59,60]. Among other functions, PKC and Ca2+ ions
synergize in the induction of dense and a-granule secretion in
platelets stimulated with agonists, such as thrombin, TXA2, and
ADP [61].6. PKCh in platelet activation
PKCh is involved in signal transduction downstream of several
different receptors, and some of its more important functions dur-
ing the platelet activation response are schematically presented in
Fig. 1. A more detailed list of potential contributions of PKCh to dif-
ferent platelet functions is presented in Table 1.6.1. The aIIbb3 integrin receptor and PKCh-regulated ‘outside-in’ and
‘inside-out’ signaling
The integrin cell adhesion molecule is regulated by both extra-
cellular and intracellular mechanisms that are essential for platelet
functions, including cytoskeletal organization, motility, aggrega-
tion, and anchorage-dependent cellular responses [62,63]. Their
involvement in platelet aggregation is regulated by an ‘inside-
out’ signals that promote conformational changes in the aIIbb3 inte-
grin receptor, thereby boost its afﬁnity for cognate ligands, such as
ﬁbrinogen. Tethering of ﬁbrinogen to aIIbb3 receptor bridges plate-
lets and promotes their activation and adhesion to sites of vascular
damage. In turn, ligand binding to the extracellular portion of the
aIIbb3 receptor triggers ‘outside-in’ signals that promote actin poly-
merization and additional cytoskeletal changes necessary to insure
efﬁcient platelet aggregation and spreading [12,64,65].
Fibrinogen is a soluble plasma glycoprotein, which functions as
a major blood-clotting component. It is synthesized in the liver and
converted by thrombin into ﬁbrin during blood coagulation [66].
While monomers of ﬁbrin polymerize into ﬁbers that further asso-
ciate in forming a ﬁbrin gel, ﬁbrinogen molecules can directly asso-
ciate with platelets aIIbb3 surface receptors, cross-link the receptor
by bridging adjacent platelets, and deliver activation signals [67].
Fibrinogen binding to platelets triggers ‘outside-in’ signals that
promote actin polymerization, cytoskeletal rearrangements and
cell spreading [12]. The signaling pathway downstream of the
aIIbb3 receptor (also termed glycoprotein IIb/IIIa, or gpIIb/IIIa) is
known to involve PKC, since PKC activators such as phorbol myris-
tate acetate (PMA) activate the platelets aIIbb3 receptor and pro-
mote platelet spreading [12]. In addition, PKCb was found to be
essential for platelet spreading on ﬁbrinogen but not for ADP- or
thrombin-induced activation of aIIbb3 [55].
A recent study that analyzed the role of PKCh in aIIbb3-linked
signaling pathways revealed that PKCh-deﬁcient platelets are im-
paired in their ability to spread on ﬁbrinogen-coated coverslips,
suggesting a positive role for PKCh in ‘outside-in’ signal transduc-
tion downstream of the aIIbb3 receptor [54]. These results were fur-
ther substantiated by Nagy et al. [68], who also utilized platelets
from PKCh/ and PKCh+/+ mice. PKCh was found to physically
and constitutively associate with the aIIbb3 receptor, both in hu-
man and mouse platelets. Stimulation of the aIIbb3 receptor with
ﬁbrinogen promoted the association of PKCh also with the Btk
and Syk PTKs, and promoted tyrosine phosphorylation of PKCh,
Btk and theWiskott–Aldrich syndrome protein (WASP). A potential
functional linkage between PKCh andWASP/WASP-interacting pro-
tein (WIP) was demonstrated in activated T cells in which PKCh-
dependent phosphorylation of WIP disengaged WASP from the
WIP-WASP complex, thereby releasing WASP from inhibition by
WIP [31]. The PKCh phosphorylation motif includes the Ser488 at
the C-terminal end of the WASP binding region of WIP. The result-
ing uncoupled WASP could then activate Cdc42 that in turn acti-
vates the Arp2/3 complex and rearrange F-actin polymerization
[69]. The above ﬁndings and additional data [70–73] suggest that
PKCh relay signals from the activated aIIbb3 receptor by regulating
the uncoupling of WASP and WIP, thereby permitting the regula-
tion of actin ﬁlament nucleation and branching activity of the
Arp2/3 complex.
Fig. 1. PKCh-mediated functions in activated platelet. A schematic model depicting PKCh and other key molecules involved in the regulation of platelet activation. Binding of
the indicated agonists to the GPVI and/or PAR receptors trigger receptor-linked signaling pathways that result in the activation of phospholipase C (PLC). PLC, in turn,
generates twomessengers, 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphtae (IP3), which activates distinct PKC isoforms and mobilizes calcium ions from intracellular
stores, respectively. Thrombin-induced DAG formation in platelets promotes the translocation of PKCh to the membrane, where it can undergo posttranslational
modiﬁcations (which may vary according to the agonist-induced signal), including phosphorylation of Thr538, Tyr90, and other residues. PKCh physically and constitutively
associate with the aIIbb3 receptor, and upon ﬁbrinogen binding to aIIbb3, PKCh associates with the Btk and Syk protein tyrosine kinases, and promote the phosphorylation of
the Wiskott–Aldrich syndrome protein (WASP)-interacting protein (WIP). PKCh also phosphorylates the tSNARE protein, syntaxin-4, which may inﬂuence granule secretion,
activates the ERK protein and thereby promotes the generation of thromboxane A2, contributes to the regulation of aIIbb3-linked ‘outside-in’ signaling, and potentially affect
the ‘inside-out’ signaling pathway. All PKCh-dependent phosphorylation events are either directly mediated by PKCh, or indirectly, by PKCh-regulated kinases. Altogether,
PKCh appears to be involved in the regulation of a-granule secretion, platelet adhesion, spreading, and aggregation. Most ﬁndings described herein were reported in recently
published manuscripts, and obtained using a variety of experimental systems. The effects of PKCh on selected cellular processes are still controversial and require further
substantiation.
Table 1
Summary of reported PKC-theta-regulated functions in platelets.
(1) Platelet functions that are positively regulated by PKCh
Platelet adhesion to ﬁbrinogen-coated cover slips, spreading, and increased generation of ﬁlopodia (m*) [54,76]
‘Outside-in’ signaling through aIIbb3 integrin receptor (m) [54,76]
‘Outside-in’ signaling in response to ﬁbrinogen (m) [76]
Signal transduction from PAR4 (m) [49]
Thrombin-induced platelet activation (P-selectin expression) and a-granule secretion (m) [49]
PAR1-, PAR4-, CRP-, collagen- and thrombin-induced platelet aggregation and dense granule secretion (m+h*) [49,68]
PAR1-, PAR4- and CRP-induced aIIbb3-receptor activation (‘inside-out’ signaling) (m+h) [68]
PAR1-, PAR4- and CRP-induced platelet activation (P-selectin expression) and a-granule secretion (m+h) [68]
PAR4- and CRP-induced threonine phosphorylation of syntaxin-4 (h) [68]
PAR4-, CRP- and collagen-induced release of TXA2, and activation of ERK (m) [68]
Hemostasis and termination of bleeding after vascular injury (m) [49]
In vivo thrombus formation after arterial injury (m) [68]
(2) Platelet functions that are negatively regulated by PKCh
CRP-induced GPVI-mediated a-granule secretion, and activation of aIIbb3 (m) [76]
Thrombus formation under ﬂow over a collagen-coated surface (m) [76]
Platelet adhesion to collagen or collagen-related peptide (CRP) (m) [76]
GPVI-dependent ‘inside-out’ signaling (m) [76]
(3) PKCh-related functions in platelets
PKCh constitutively associates with the aIIbb3 integrin receptor (m+h) [54]
GP Ib-V-IX- and GPVI-receptor activation (by Alboaggregin A) and vWF/ristocetin-mediated activation of the GP Ib-V-IX receptor induces PKCh association with Btk, and
PKCh-dependent threonine phosphorylation of Btk (h) [75]
Fibrinogen-induced aIIbb3 integrin receptor activation stimulates PKCh binding to Btk and Syk, and Btk- and/or Syk-mediated tyrosine phosphorylation of PKCh (h) [54]
Collagen induces Btk- and/or Syk-mediated tyrosine phosphorylation of PKCh (h) [54]
Fibrinogen-induced aIIbb3 integrin receptor activation results in PKCh-induced phosphorylation of WIP and activation of WASP (h) [54]
PAR1-induced activation by SFLLRN, PAR4-induced activation by AYPGKF, and GPVI-induced activation by CRP stimulate PKCh phosphorylation on Thr538 (h) [68]
(4) Platelet functions that are independent of PKCh
Extent of the aIIbb3 integrin receptor expression (m) [54]
Fibrinogen binding to the aIIbb3 integrin receptor following platelet activation by ADP, epinephrine, or PAR4 agonist (m) [54]
Agonist-induced ‘inside-out’ signaling (h) [54]
Fibrinogen-induced secretion of dense granules (m) [76]
Collagen- or CRP-induced platelet aggregation (m) [76]
* m, mouse; h, human.
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duction of agonist-induced ‘inside-out’ signals, neither for ﬁbrino-
gen binding to aIIbb3 receptor. In contrast, Nagy et al. [68] have
demonstrated that PKCh-deﬁcient platelets are impaired in GPVI-
and PAR4-induced activation of the aIIbb3 receptor, suggesting that
PKCh plays a positive role in the ‘inside-out’ signaling pathway that
regulate the activation of the aIIbb3 receptor. The latter study is
indirectly supported by the results of Sun et al., demonstrating that
decreased expression levels of PKCh, that are secondary to a muta-
tion in RUNX1, are in correlation with an impaired ‘inside-out’ sig-
nal transduction-dependent activation of the aIIbb3 receptor [74].
The reason for the discrepancy between these studies is not clear,
although it may reﬂect usage of different assay systems and/or
experimental conditions.
6.2. PKCh-mediated signaling via the receptors for collagen
(glycoprotein VI) and von Willebrand factor (GPIb-V-IX)
Studies in human and mouse platelets supported a role for PKCh
in signaling from the receptors for collagen (glycoprotein VI; GPVI)
and von Willebrand factor (vWF) (GPIb-V-IX) [68,75,76], although
the exact role of PKCh in these signaling pathways is still under
debate. Stimulation of GPVI by CRP or collagen is known to induce
a-granule and dense granule secretion from platelets, and Poole
and co-workers reported that granule secretion in CRP-treated
PKCh-deﬁcient platelets was increased compared to the response
of wild type platelets [76,77]. In contrast, Kunapuli and co-workers
reported that CRP-induced granule secretion by murine PKCh-
deﬁcient plateletswas decreasedwhen comparedwith their normal
counterparts [68,78]. The latter ﬁndings were further substantiated
in a study utilizing human platelets, wherein a PKCh antagonistic
peptide (that blocks the speciﬁc receptor for activated C kinase;
RACK) inhibited CRP- and collagen-induced granule secretion [68].
In this study, inhibition of PKCh correlated with reduced threonine
phosphorylation of the tSNARE protein, syntaxin-4, following GPVI
or PAR4 activation. Because tSNARE proteins play a positive role in
processes of vesicle exocytosis, it is suggested that PKCh regulates
granule secretion through syntaxin-4 phosphorylation [68,78].
While some of the discrepancy in the results could be explained by
usage of different concentrations of CRP to stimulate platelets, addi-
tional studies are required in order to determine which of the sug-
gested mechanisms are physiological and describes the actual
effect of PKCh on the in vivo response of GPVI-stimulated platelets.
In a different line of studies, Crosby and Poole [75] have used
alboaggregin A (a snake venom-derived C-type lectin that is capable
of activating GPVI and GPIb-V-IX in combination), or vWF/ristocetin
(an Amycolatopsis lurida-derived agglutinating antibiotic) to stimu-
late human platelets. They found that both types of treatments have
led to a rapid tyrosine phosphorylation of Btk. Phosphorylation of
Btkwas likely to bemediated by a Src-family PTK since it was sensi-
tive to inhibition by PP1. Platelet stimulation with the above ago-
nists also resulted in Btk phosphorylation on threonine residues,
apparently by a PKC enzyme, and coimmunoprecipitation of Btk
with PKCh, but notwith eight other PKC isoforms tested. Association
with PKCh was mediated by the Btk N-terminal PH domain, and at
least in Mast cells, a similar association involved the C1 domain of
PKC [79]. Platelet activation by alboaggregin A or vWF/ristocetin
also induced Src- or Btk-dependent phosphorylation of PKCh on
tyrosine residues. While the exact phosphorylation site on PKCh
has not been identiﬁed in thiswork, Tyr90 in the PKCh regulatory do-
mainwas a preferred candidate, because it was identiﬁed as amajor
target of phosphorylation by Lck in TCR activated T cells [80]. In a
more recent study, Tyr90 was found to be a major phosphorylation
site in collagen activated human platelets [54]. However, ﬁbrinogen
binding to the aIIbb3 integrin receptor induced tyrosine phosphory-
lation of PKCh, which did not react with phospho-Tyr90-speciﬁc Abs.This suggests that platelet activation via different cell surface recep-
torsmay involve the activationof distinct PTKs andphosphorylation
of PKCh on tyrosine residues located at different sites. Additional
work is required in order to identify the phosphorylation sites on
PKCh, and determine the PTKs involved in the phosphorylation of
the individual residues. Nevertheless, our understanding of the
mechanisms by which PKCh regulate platelet functions will be
incomplete before clarifying how these posttranslational effects im-
pact on PKCh ability to interact with other effector molecules, alter
its catalytic activity, and/or modulate its subcellular location.
6.3. PKCh-mediated signaling from PAR receptors
The protease-activated receptor (PAR) family includes four
known isoforms of heterotrimeric G protein-coupled receptors
[81,82], among which the PAR1 and PAR4 are expressed on human
platelets [81], whereas mouse platelets express the PAR3 and PAR4
[83,84]. PARs are activated by serine proteases, such as thrombin
(acts on PARs 1, 3 and 4) and trypsin (acts on PAR2) that cleave part
of the N-terminal extracellular domain of the receptor [85]. The
cleaved portion of the receptor acts as the agonist, causing receptor
activation and promoting a physiological response – a secretion of
intracellular granules and release of their content into the sur-
roundings. Thrombin-induced activation of PAR receptors initiates
a signaling cascade involving the activation of PLC and the rapid
translocation of PKCh from the cytosol to the membrane fraction
[49]. These data indicate a positive role for PKCh in signal transduc-
tion downstream of the PAR receptors.
To further analyze the involvement of PKCh in thrombin-in-
duced PAR receptor-linked signal transduction pathways, platelets
from PKCh/ mice and wild type mice were stimulated with
thrombin, and their responses were monitored and compared.
PKCh-deﬁcient platelets responded less efﬁciently in aggregation
and redistribution of the P-selectin, CD62P, to the plasma mem-
brane [49]. CD62P is a constitutively expressed integral glycopro-
tein of the a-granule membrane [86]. It is rapidly redistributed
from the a-granule’s membrane to the outer cell surface following
platelet activation [87]. The plasma membrane expressed CD62P
serves as an adhesion receptor that can interact with P-selectin
glycoprotein ligand-1 (PSGL-1) on the surface of leukocytes, there-
by promoting platelet-leukocyte adhesion, leukocyte activation
and adhesion to endothelial cells, and trans-migration to sites of
inﬂammation [88,89]. Expression of CD62P on the outer surface
of platelets directly correlates with platelet degranulation and
secretion, and therefore serves as a marker of platelet activation
[90–92].
A positive regulatory role for PKCh in PAR-linked signaling path-
ways was demonstrated by Nagy et al. [68] in human and mouse
platelets. In their studies, human platelets were pretreated with
a control peptide or a PKCh-selective antagonistic peptide for RACK
(receptor for activated C kinase), and stimulated by the PAR1-spe-
ciﬁc agonist, SFLLRN (single letter amino acid code), or the PAR4-
speciﬁc agonist, AYPGKF. In their studies, inhibition of PKCh re-
sulted in impaired PAR-induced a-granule and dense granule
secretion and platelet aggregation. Similar results were obtained
in PKCh-deﬁcient murine platelets that poorly responded in gran-
ule secretion and aggregation following stimulation with the
PAR4 agonist, SFLLRN.
It is interesting to note that PAR1-, PAR2- and PAR3-induced
activation of Jurkat T cells promoted tyrosine phosphorylation of
VAV1, ZAP-70 and SLP-76, key effector molecules in signal trans-
duction downstream of the TCR [93]. Whether these PAR-induced
signaling pathways in T cells are dependent or independent of
PKCh is not clear at present, and this requires the analysis of PAR
receptor activation mechanisms in T lymphocytes from PKCh-deﬁ-
cient mice.
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following blood vessel injury
Platelet activation is crucial for normal hemostasis and preven-
tion of excessive bleeding. Upon vascular injury, platelets are rap-
idly recruited to the damaged site where they form a hemostatic
plug that arrests bleeding. The potential involvement of PKCh in
the regulation of platelet functions, as outlined above, suggests that
PKCh may play a role in processes that regulate hemostasis. In a
study by Cohen et at., the effect of PKCh on bleeding time was mon-
itored in PKCh/ and PKCh+/+ mice following tail tip amputation.
The bleeding time was found to be signiﬁcantly longer in PKCh/
mice compared to that of their wild type counterparts [49]. Because
the defect was observed in both C57BL/6J-PKCh/ and BALB/C-
PKCh/ mice, it is assumed that the impaired hemostasis is PKCh-
dependent rather than a genetically inherited mouse strain speciﬁc
trait.
Nagy et al. [68] have also analyzed the in vivo function of mur-
ine platelets from a PKCh/ mouse origin. Utilizing the FeCl3 car-
otid artery-injury model, they found that PKCh/ mice exhibited
a prolonged time of occlusion and failed to form a stable thrombus
in response to injury. Their ﬁndings supported the idea that PKCh is
essential for stabilizing thrombus formation after arterial injury.
The bleeding time of PKCh/mice was also tested by Soriani et
al. [54], who reported no obvious defects due to PKCh-deﬁciency.
However, their actual data were unpublished and it is not clear
what type of assay they have utilized in their work.
8. RUNX1 regulation of PKCh gene transcription and PKCh
protein expression in platelets
Characterization of different genetically engineered and knock-
out mouse models, as well as human diseases revealed that hema-
topoietic transcription factors might be associated with
thrombocytopenia and platelet dysfunctions [94–96]. A human
inherited deﬁciency of the RUNX1 (also termed core-binding fac-
tor A2; CBFA2) transcription factor, characterized by thrombocyto-
penia and platelet dysfunction [96], was found to be associated
with reduced expression of PKCh in platelets [74]. Furthermore,
platelets from this patient were impaired in their ability to
respond via the aIIbb3-receptor, aggregate, and induce the phos-
phorylation of pleckstrin, the major PKC substrate that undergoes
serine/threonine phosphorylation in response of human platelets
to thrombin stimulation [97,98]. The pleckstrin protein associates
with inositol polyphosphate 5-phosphatase I (5-phosphatase I),
and upon its phosphorylation by PKC [99], it turns on the 5-phos-
phatase I activity [100]. This enzyme in turn hydrolyzes the
5-phosphate from inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and
inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4), thereby termi-
nating the inositol phospholipid-stimulated calcium mobilization
[101].
The studies by Jalagadugula and co-workers demonstrated that
RUNX1 directly associates with a speciﬁc site in the PKCh gene
(PRKCQ) promoter in megakaryocytic cells, and further showed
that siRNA-induced silencing of RUNX1 inhibited PRKCQ promoter
activity and PKCh protein expression [102]. The results indicate
that PRKCQ is regulated at the transcriptional level by RUNX1,
and explains the reduction in PKCh protein levels, and PKCh-regu-
lated functional activities in platelets of the patient with the mu-
tated RUNX1. Additional studies are required to determine
whether RUNX1 is a cell lineage-speciﬁc transcription factor that
regulates gene expression in megakaryocytes, but not T cells.
Should the RUNX1 also regulate gene transcription in T cells, it
would be of interest to test the effect of the mutated RUNX1 on
PRKCQ gene transcription and analyze whether it affects PKCh-reg-
ulated T cell functions.9. Conclusions
PKCh appears to be an important regulator of signal transduction
downstream of the GPVI-, aIIbb3 integrin- and PAR-receptors in
mouse and human platelets. Its absence results in impaired hemos-
tasis, platelet aggregation, and thrombus formation. However, addi-
tional studies indicate that platelet functions are regulated by
several distinct PKC isoforms, which can synergize or antagonize
the effects of PKCh, or affect platelet functions independently of
PKCh [47,48,53,55–57,103,104]. Distinct PKC isoforms can also be
involved in signal transduction from the same receptor or from dif-
ferent surface receptors. Furthermore, some PKC isoforms can reg-
ulate speciﬁc functions, such as granule secretion, while othersmay
be involved in platelet adhesion to cells or extracellular matrices.
Understanding the role of individual PKC isoforms in the regulation
of distinct platelet functions, in combination with isoform-speciﬁc
drugs, could potentially provide improved means for the treatment
of selected platelet-mediated pathologies. While highly speciﬁc
inhibitors of distinct PKC isoforms are not yet available, studies uti-
lizing the different mouse PKC knockout models can provide a
plethora of valuable information.Acknowledgement
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